The Kinetics and Extent of Engraftment of Chronic Myelogenous Leukemia Cells in Non-Obese Diabetic/Severe Combined Immunodeficiency Mice Reflect the Phase of the Donor’s Disease: An In Vivo Model of Chronic Myelogenous Leukemia Biology
Open Access
- 15 August 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 92 (4) , 1390-1396
- https://doi.org/10.1182/blood.v92.4.1390
Abstract
In vitro studies have provided little consensus on the kinetic abnormality underlying the myeloid expansion of chronic myelogenous leukemia (CML). Transplantation of human CML cells into non-obese diabetic mice with severe immunodeficiency disease (NOD/SCID mice) may therefore be a useful model. A CML cell line (BV173) and peripheral blood cells collected from CML patients in chronic phase (CP), accelerated phase (AP), or blastic phase (BP) were injected into preirradiated NOD/SCID mice. Animals were killed at serial intervals; cell suspensions and/or tissue sections from different organs were studied by immunohistochemistry and/or flow cytometry using antihuman CD45 monoclonal antibodies (MoAbs), and by fluorescence in situ hybridization (FISH) for the BCR-ABL fusion gene. One hour after injection, cells were sequestered in the lungs and liver, but 2 weeks later they were no longer detectable in either site. Similar short-term kinetics were observed using51Cr-labeled cells. The first signs of engraftment for BV173, AP, and BP cells were detected in the bone marrow (BM) at 4 weeks. At 8 weeks the median percentages of human cells in murine marrow were 4% (range, 1 to 9) for CP, 11% (range, 5 to 36) for AP, 38.5% (range, 18 to 79) for BP, and 54% (range, 31 to 69) for BV173. CP cells progressively infiltrated BM (21%) and spleen (6%) by 18 to 20 weeks; no animals injected with the cell line or BP cells survived beyond 12 weeks. The rate of increase in human cell numbers was higher for BP (7.3%/week) as compared with CP (0.9%/week) and AP (0.5%/week). FISH analysis with BCR and ABL probes showed that some of the human cells engrafting after injection of CP cells lacked a BCR-ABL gene and were presumably normal. We conclude that CML cells proliferate in NOD/SCID mice with kinetics that recapitulate the phase of the donor’s disease, thus providing an in vivo model of CML biology. © 1998 by The American Society of Hematology.Keywords
This publication has 23 references indexed in Scilit:
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- Severe Combined Immunodeficiency Mice Engrafted With Human T Cells, B Cells, and Myeloid Cells After Transplantation With Human Fetal Bone Marrow or Liver Cells and Implanted With Human Fetal Thymus: A Model for Studying Human Gene TherapyBlood, 1997
- Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapyNature Medicine, 1996
- Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID miceBlood, 1996
- Abnormal kinetics of colony formation by erythroid burst‐forming units (BFU‐E) in chronic myeloid leukaemiaBritish Journal of Haematology, 1996
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Treatment of Philadelphia‐chromosome‐positive human leukemia in scid mouse model with herbimycin A, bcr‐abl tyrosine kinase activity inhibitorInternational Journal of Cancer, 1995
- Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemiaBlood, 1994
- Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level.Proceedings of the National Academy of Sciences, 1992
- Circulating Granulocytic and Erythroid Progenitor Cells in Chronic Granulocytic LeukaemiaBritish Journal of Haematology, 1980